Primobolan (Methenolone Enanthate)

Methenolone is a DHT derivative with a 1-methyl modification and an additional double bond at the C1-2 position. It binds to the androgen receptor with moderate affinity and exhibits an anabolic-to-androgenic ratio of approximately 88:44 (relative to testosterone at 100:100). It cannot be aromatized to estrogen due to its DHT-derived structure. Methenolone has been shown to directly enhance immune function, possibly through upregulation of immune cell AR expression. It has strong anti-catabolic properties, binding to glucocorticoid receptors and interfering with cortisol-mediated muscle catabolism. It enhances nitrogen retention effectively even at moderate doses, making it particularly useful during caloric restriction. Unlike many AAS, it does not significantly increase IGF-1 levels.

Methenolone Enanthate is slowly absorbed from the intramuscular injection site. Peak plasma levels are reached in 2-4 days with a terminal half-life of 7-10 days. Steady-state is achieved in approximately 5-6 weeks. The compound undergoes hepatic metabolism but is NOT c17-alpha alkylated, meaning it poses minimal hepatotoxic risk. Metabolites are primarily excreted in urine. The enanthate ester provides sustained release suitable for twice-weekly injection. Due to the moderate receptor binding affinity, higher milligram doses are needed compared to more potent AAS to achieve equivalent anabolic effects.

• ✓Exceptional safety profile with minimal side effects
• ✓No aromatization to estrogen (zero water retention)
• ✓Effective lean muscle preservation during caloric deficit
• ✓Mild but steady lean muscle gains during surplus
• ✓Minimal liver toxicity (not c17-alpha alkylated)
• ✓Low androgenic side effects (gentle on hair, skin, and prostate)
• ✓Enhances nitrogen retention and immune function
• ✓Suitable for longer cycles due to mild nature

• ⚠Weaker milligram-for-milligram than most other AAS (requires higher doses)
• ⚠Expensive due to high raw material costs and required higher dosages
• ⚠Mild HPTA suppression (still requires PCT)
• ⚠Some androgenic effects possible (acne, hair thinning) though much less than most AAS
• ⚠Subtle results may disappoint users expecting dramatic changes
• ⚠Mild negative impact on lipid profile at higher doses
• ⚠Commonly counterfeited or underdosed due to high cost

Contraindications

• 🚫Severe cardiovascular disease
• 🚫Liver disease (though primobolan is minimally hepatotoxic)
• 🚫Prostate cancer
• 🚫Pregnancy
• 🚫Hypersensitivity to methenolone or carrier oil
• 🚫Budget constraints (primo requires high doses and is expensive)

Begin PCT 14 days after the last Primobolan injection. Primobolan is less suppressive than most AAS, so recovery is generally smoother. Standard PCT: Nolvadex 20mg/day for 4-6 weeks, or Clomid 50mg/day for 3-4 weeks. HCG during cycle at standard doses is beneficial but less critical than with more suppressive compounds. Bloodwork 4-6 weeks after PCT to confirm recovery.

• 1.Budget for higher doses; 400mg/week is a minimum effective dose and most experienced users run 600-1000mg/week
• 2.Verify your source quality; primobolan is one of the most commonly faked or underdosed compounds on the market
• 3.Primobolan pairs exceptionally well with testosterone for a relatively safe and effective cycle
• 4.Extended 16-20 week cycles are ideal due to the mild nature; short cycles yield underwhelming results
• 5.One of the best compounds for athletes who need to pass drug tests outside of the detection window, though the 4-5 month detection time still requires planning
• 6.Female users can consider primobolan at 50-100mg/week as one of the safer injectable options for women

1. [1]Schering AG. Primobolan Depot prescribing information.
2. [2]Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
3. [3]Methenolone enanthate pharmacokinetics. Drug Metabolism Reviews. 1995.
4. [4]Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57:411-434.